Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  Immunotherapy, tissue phenomics, tissue biomarkers, cancer immunotherapy, diagnostics, tissue-based diagnostics, io-panel

The Power of Predictive Quantitative Tissue-Based Diagnostics in Cancer Immunotherapy

Nov 21, 2017 8:00:00 AM

The American Society of Clinical Oncology named Immunotherapy 2.0 “Advance of the Year” at its 2017 Annual Meeting in Chicago, IL. This recognition comes after decades of incremental progress in our understanding of how the human immune system interacts with cancerous lesions. It also is the culmination of recent successes with checkpoint inhibitor therapy that promised dramatic changes in clinical practice and the approach to cancer treatment. What started with cutaneous melanoma in 2011 is now rapidly showing remarkable results also in other
cancer types. Just over the past year, the Food and Drug Administration (FDA) approved the use of checkpoint inhibitors in five additional cancer indications: lung, head and neck, bladder, kidney, and classical Hodgkin lymphoma.

Read More

Topics:  Immunotherapy, immuno-oncology, cancer immunotherapy

Definiens’ Favorite Videos on Immunotherapy

Jun 13, 2016 6:57:52 AM

Cancer immunotherapy is cutting edge science and video is currently the most popular tool in digital media to learn and communicate. For the hot topic of Immunotherapy there are currently almost 400 thousand videos available on the web. For just Cancer Immunotherapy there are still more than 15 thousand. Who would have the patience to watch all these and find the best ones? We do. Four Definiens experts searched the web for their most favorite videos about cancer immunotherapy.  Check it out below.

Read More

Topics:  Immunotherapy, immune system, case study, Immunooncology, cancer immunotherapy

New Case Study: Comprehensive Assessment of the Inflammatory Tumor Microenvironment

Jun 24, 2014 12:32:00 PM

Combat or Surveillance? Why morphology and spatial relationships are key to describe the functional state of the immune system.

Understanding the cellular and molecular mechanisms of the inflammatory tumor microenvironment is becoming increasingly important as cancer immunotherapies are the focus of almost all pharmaceutical companies.

This study presents a novel way of comprehensively characterizing the immune cell-tumor cell interaction, with implications for biomarker discovery and increased disease understanding.

Download your copy of Definiens' case study Comprehensive Assessment of the Inflammatory Tumor Microenvironment to learn more.

 

Read More

Topics:  drug development, Immunotherapy, immuno-oncology, biomarkers, cancer research, cancer immunotherapy

Cancer Immunotherapy: Featured News Articles Of The Month (June, 14)

Jun 18, 2014 3:39:00 AM

Scientists Prime The Immune System As A Powerful Cancer Weapon

Review of ASCO starting with the summary of a proof-of principle study presented by NCI answering the question if T-cells could be utilized to fight solid tumors.
http://www.forbes.com/sites/matthewherper/2014/06/02/scientists-prime-the-immune-system-as-a-powerful-cancer-weapon/


Our immune systems can unmask tumours and cure cancer, experts say, calling immuno-oncology the biggest breakthrough in years

Review of cancer immunotherapy study results from several drug companies recently presented at ASCO conference including comments to the status of Immunotherapy by several oncology experts from pharmaceutical industry and academic research such as David Hafler (Yale University), Dr. Roy Baynes (senior vice-preseident of clinical research at Merck) and Michael Giordano (Head of Oncology at BMS).
http://news.nationalpost.com/2014/06/09/our-immune-systems-can-unmask-tumours-and-cure-cancer-experts-say-calling-immuno-oncology-the-biggest-breakthrough-in-years/


Pharma vies to unleash immune system power on cancer

An overview of ongoing cancer immunotherapy trials and related achievements of the major drug companies chasing to get a share of the estimated enormous market potential of immuno-oncology drugs.
http://www.rsc.org/chemistryworld/2014/06/pharma-vies-unleash-immune-system-power-cancer

Read More

Topics:  drug development, Immunotherapy, Whitepaper, immuno-oncology, biomarkers, cancer research, cancer immunotherapy

New Whitepaper: An Introduction to Immunotherapy and the Promise of Tissue Phenomics™

Jun 11, 2014 3:52:00 AM

Nearly every day there seems to be exciting news or developments in the field of immunotherapy and immuno-oncology. Not only can you read all about immunotherapy research in leading scientific journals (1), but the mainstream media now reports on the latest immunotherapy clinical trial results from pharmaceutical companies.

But what exactly is immunotherapy and what technologies are needed to realize its full potential for the treatment of cancer? Throughout this whitepaper, Definiens will answerthose questions as well as provide insight into other commonly asked questions about immunotherapy:

  • Why is it predicted that 60% of cancer treatments will be based on immunotherapy in the next 10 years?
  • What are some of the more common approaches to immunotherapy today?
  • What will be needed to accurately identify patients that will respond to immunotherapy treatment?
  • How can knowing a patient’s immune status predict long-term treatment success?
  • How is the use of Tissue Phenomics™ enabling effective clinical decision-making in oncology?

Download your copy of An Introduction To Immunotherapy And The Promise Of Tissue Phenomics™ to learn more.

Read More